Antibodies that bind IL-4 and/or IL-13 and their uses

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10759871
APP PUB NO 20180030156A1
SERIAL NO

15645765

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to novel humanized anti-IL-4 and IL-13 antibodies and fragments thereof and novel bispecific antibodies and fragments thereof that specifically bind to IL-4 and IL-13. The invention also includes uses of the antibodies to treat or prevent IL-4 and/or IL-13 mediated diseases or disorders, including allergic asthma and dermatitis.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
SANOFI54 RUE LA BOÉTIE PARIS 75008

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Davison, Matthew Long Valley, US 24 234
Kruip, Jochen Erzhausen, DE 38 301
Li, Danxi Skillman, US 60 430
Mikol, Vincent Charenton-le-Pont, FR 48 648
Rao, Ercole Morfelden-Waldorf, DE 59 535

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Mar 1, 2028
11.5 Year Payment $7400.00 $3700.00 $1850.00 Mar 1, 2032
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00